MARKET

MDWD

MDWD

Mediwound
NASDAQ
1.390
+0.040
+2.96%
Closed 16:00 09/23 EDT
OPEN
1.410
PREV CLOSE
1.350
HIGH
1.440
LOW
1.310
VOLUME
205.02K
TURNOVER
182.14K
52 WEEK HIGH
4.010
52 WEEK LOW
1.210
MARKET CAP
46.07M
P/E (TTM)
-2.6138
1D
5D
1M
3M
1Y
5Y
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers
Benzinga · 2d ago
Dow Turns Higher; Crude Oil Rises 0.7%
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday.
Benzinga · 2d ago
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
 Gainers
Benzinga · 3d ago
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
Benzinga · 3d ago
Sector Update: Health Care Stocks Gain Thursday Afternoon
Sector Update: Health Care Stocks Gain Thursday Afternoon
MT Newswires · 3d ago
Spero, HeartBeam top healthcare gainers; MediWound, Vincerx lead losers' pack
Gainers: Spero Therapeutics SPRO +135%. HeartBeam (BEAT) <font co...
Seekingalpha · 3d ago
Sector Update: Health Care Stocks Rising in Defensive Thursday Trading
Sector Update: Health Care Stocks Rising in Defensive Thursday Trading
MT Newswires · 3d ago
MediWound stock slips on ~$30.5M securities offerings
MediWound (NASDAQ:MDWD) shares dropped 17% premarket o...
Seekingalpha · 3d ago
More
About MDWD
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Webull offers kinds of Mediwound Ltd stock information, including NASDAQ:MDWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDWD stock methods without spending real money on the virtual paper trading platform.